Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth

Cancer Res. 2013 Dec 1;73(23):7009-21. doi: 10.1158/0008-5472.CAN-13-1075. Epub 2013 Oct 11.

Abstract

One classical feature of cancer cells is their metabolic acquisition of a highly glycolytic phenotype. Carbon monoxide (CO), one of the products of the cytoprotective molecule heme oxygenase-1 (HO-1) in cancer cells, has been implicated in carcinogenesis and therapeutic resistance. However, the functional contributions of CO and HO-1 to these processes are poorly defined. In human prostate cancers, we found that HO-1 was nuclear localized in malignant cells, with low enzymatic activity in moderately differentiated tumors correlating with relatively worse clinical outcomes. Exposure to CO sensitized prostate cancer cells but not normal cells to chemotherapy, with growth arrest and apoptosis induced in vivo in part through mitotic catastrophe. CO targeted mitochondria activity in cancer cells as evidenced by higher oxygen consumption, free radical generation, and mitochondrial collapse. Collectively, our findings indicated that CO transiently induces an anti-Warburg effect by rapidly fueling cancer cell bioenergetics, ultimately resulting in metabolic exhaustion.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology
  • Carbon Monoxide / administration & dosage
  • Carbon Monoxide / pharmacology*
  • Cell Proliferation / drug effects*
  • Cells, Cultured
  • Drug Resistance, Neoplasm / drug effects
  • Drug Synergism
  • Energy Metabolism / drug effects*
  • HeLa Cells
  • Hep G2 Cells
  • Humans
  • Mice
  • Mice, Nude
  • Mice, Transgenic
  • NIH 3T3 Cells
  • Neoplasms / drug therapy
  • Neoplasms / metabolism*
  • Neoplasms / pathology*

Substances

  • Antineoplastic Agents
  • Carbon Monoxide